Based on the State Enterprise "Medical Procurements", innovative medicines for combating cancer diseases will be produced.
As reported by the press service of SE "Medprocurement" on Facebook, an agreement on the localization of innovative oncology drug production has been signed with the international pharmaceutical company Roche during the Ukraine Recovery Conference 2025 in Rome.
"This is the first time our state enterprise is becoming a full-fledged partner of a global leader in the development of innovative medicines! Under the investment agreement, the Swiss company Roche will supply pharmaceutical products to Ukraine in bulk – ready for packaging. Our branch «Medpostachannya» will handle the final packaging, labeling, and delivery to patients," the statement reads.
This will significantly reduce the cost of drugs and consequently increase the number of patients receiving modern treatment.
"According to Roche's estimates, over the next 5 years, the investment agreement will provide medicines for more than 5,800 patients," SE "Medprocurement" noted.
In particular, they will procure medicines for the two most common types of cancer in Ukraine:
- Atezolizumab (“Tecentriq”) — for treating non-small cell lung cancer;
- Pertuzumab + Trastuzumab (“Phesgo”) — for treating HER2-positive breast cancer.
Ukrainian patients will be able to receive medicines with localized production as early as 2027.
This collaboration will significantly lower the cost of drugs, develop pharmaceutical manufacturing in Ukraine, and ensure stable access to treatment.
On July 10-11, the fourth International Conference on Ukraine's Recovery (URC2025) will take place in Rome, attended by the President of Ukraine and heads of European states.
The forum will continue a series of high-level political initiatives dedicated to the rapid recovery and long-term reconstruction of Ukraine, which is suffering from external aggression. This time, the Ukrainian delegation will focus on presenting practical projects that are already being implemented even in wartime or have a high degree of readiness for implementation.
